Aminoacids and derivatives

<p>Applications Antifibrinolytic agent. Used in the preparation of Tranexamic Acid (T714505).<br></p>

<p>Applications (S)-Ethyl 2-amino-3-(1H-indol-3-yl)propanoate hydrochloride (cas# 2899-28-7) is a useful research chemical.<br></p>

<p>Applications 1-Methyl-D-tryptophan is used in biological studies to determine the effect of IDO2 enzyme (indoleamine-(2,3)-dioxygenase) activity and IDO2-mediated arrest of human T cell proliferation. It reverses IDO-mediated immune suppression<br>References Qian, F., et al.: Cancer Immunology Immunothrapy, 61, 2013 (2012)<br></p>

<p>Stability Unstable in Solution<br>Applications (S)-(-)-Carbidopa is a peripheral decarboxylase inhibitor that is commonly used in combination with L-DOPA (D533751) for treatment of Parkinsonism. S(-)-Carbidopa ( has also been shown to prolong the elimination half-life of L-DOPA from blood plasma and skeletal muscle.<br>References Henry, G.M. et al.: Psychosom. Med., 38, 95 (1976); Leguire, L.E. et al.: Invest. Ophthalmol. Vis. Sci. 34, 3090 (1993); Deleu, D. et al.: Naun. Schmied. Arch. Pharmacol. 348: 576 (1993);<br></p>

<p>Applications Glycine-d2, is the labeled analogue of Glycine (G615990), a non-essential amino acid for human development. Glycine is an inhibitory neurotransmitter in spinal cord, allosteric regulator of NMDA receptors.<br>References Scott, D., et al.: J. Neurosci., 21, 3063 (2001); Laube, B., et al.: Neuropharmacology, 47, 994 (2004); Papadakis, M., et al.: J. Biol. Chem., 279, 14703 (2004), Chen, P., et al.: Mol. Pharmacol., 67, 1470 (2005), Wolosker, H., et al.: Mol. Neurobiol., 36, 152 (2007);<br></p>

<p>Applications L-Histidine Monohydrochloride Monohydrate is a histamine precursor via histidine decarboxylase. Also, they are grown as crystals which possesses anti-bacterial activity.<br>References Chandra, J. S., et al.: World J. Pharm. Res., 4, 1408-1429 (2015)<br></p>

<p>Stability Hygroscopic<br>Applications Indole-3-acetyl-L-aspartic Acid is an indole-3-acetyl-amino acid conjugate involved in regulatory mechanisms for the control of auxin activity during physiological and pathophysiological responses.<br>References Ostrowski, M., et al.: J Plant Physiol, 191, 63-72 (2016)<br></p>

<p>Trans-trans-4,4'-Iminodimethylenedi(cyclohexanecarboxylic acid) is a hydrophobic particle that is soluble in water. It has an average particle diameter of 20 nm and a viscosity of 10 cps. Trans-trans-4,4'-Iminodimethylenedi(cyclohexanecarboxylic acid) is used in skin care products as a thickener and viscosity enhancer. It provides a silky feel to the skin and improves the skin's elasticity. This product also helps to protect the skin from UV radiation by forming a barrier on the surface of the skin. The natural polymer can be produced from glycerin or amide to produce different properties for different applications. Trans-trans-4,4'-Iminodimethylenedi(cyclohexanecarboxylic acid) is an amphoteric molecule that can react with both acidic</p>

<p>Trans-4-(aminomethyl)cyclohexanecarboxylic acid (AMCA) is a histamine antagonist that is used to treat bowel disease. It may also be useful for the treatment of other inflammatory diseases and as an anticoagulant. AMCA has been shown to be safe and effective for the prevention of postoperative bleeding in patients who are undergoing major surgery. This drug is a potent inhibitor of platelet aggregation, but does not affect the function of erythrocytes or leukocytes. AMCA inhibits platelet aggregation by blocking the binding of adenosine diphosphate (ADP) to its receptor on platelets, thus inhibiting ADP-mediated activation of phospholipase A2 and arachidonic acid release from membranes. An increase in blood levels of AMCA may lead to cardiac toxicity and bleeding events.</p>

<p>Carbidopa is an impurity of the drug L-DOPA, which is used as a treatment for Parkinson's disease. Carbidopa is a prodrug that is converted to L-DOPA by decarboxylase, an enzyme in the body. The conversion process can be inhibited by the presence of carbidopa impurity F (CIF), which binds to carboxamides and forms a stable complex with them. This prevents CIF from binding to decarboxylase and blocking its ability to convert carbidopa into L-DOPA. CIF has been shown to have anti-parkinsonian effects by reducing the severity of symptoms associated with Parkinson's disease such as muscular rigidity and tremors.</p>

<p>UNC0224 is a selective inhibitor of G9a with a Ki of 2.6 nM and IC50 of 15 nM. UNC0224 also potently inhibits GLP with assay-dependent IC50 values of 20-58 nM.</p>

<p>Carbidopa Impurity 2 is an impurity of carbidopa, a drug product that is used to treat Parkinson's disease. Carbidopa Impurity 2 is an analytical standard for the identification and quantification of carbidopa in biological samples. The natural form of this compound is unknown, but it has been synthesized using custom synthesis techniques. This compound was also used to develop a high purity HPLC standard and as a pharmacopoeia reference material.</p>

<p>L-5-BromoTryptophan (5-BrW) is an analog of the tryptophan (Trp) effector and inhibits the gelation of hemoglobin S.</p>

<p>Edrophonium: quick-acting, brief cholinesterase inhibitor for arrhythmias, myasthenia gravis diagnosis, and curare antidote.</p>

<p>V-9302 (V9302) is a competitive antagonist of transmembrane glutamine flux that selectively and potently targets the amino acid transporter ASCT2 (IC50: 9.6 uM</p>